NEW YORK (GenomeWeb News) - Life Technologies has denied all allegations in a lawsuit that former Visigen Biotechnologies CEO and Co-founder Susan Hardin filed in October 2009 against Life Tech, its Invitrogen unit, and Visigen, alleging breach of contract, fraud, negligent representation, and breach of fiduciary duty regarding Invitrogen's 2008 acquisition of Visigen, according to GenomeWeb Daily News sister publication In Sequence.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.